Lasa Supergenerics Share Price
Sector: Biotechnology & Drugs
10.29 +0.49 (5.00%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
10.29
Today’s High
10.29
52 Week Low
8.52
52 Week High
33.49
10.24 +0.48 (4.92%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
10.24
Today’s High
10.24
52 Week Low
8.42
52 Week High
33.49
Key Metrics
- Market Cap (In Cr) 51.55
- Beta 1.23
- Div. Yield (%) 0
- P/B 0.61
- TTM P/E -
- Sector P/E 0
- D/E 0
- Open Price 10.29
- Prev Close 9.8
Lasa Supergenerics Analysis
Price Analysis
-
1 Week4.07%
-
3 Months-39.23%
-
6 Month-61.12%
-
YTD-59.75%
-
1 Year-55.75%
Risk Meter
- 64% Low risk
- 64% Moderate risk
- 64% Balanced Risk
- 64% High risk
- 64% Extreme risk
Lasa Supergenerics News
Stocks to Watch: TCS, Tata Motors, Tata Steel, Axis Bank, Vodafone Idea
2 min read . 11 Apr 2022Lasa Supergenerics Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 142.45
- Selling/ General/ Admin Expenses Total
- 6.11
- Depreciation/ Amortization
- 12.3
- Other Operating Expenses Total
- 23.89
- Total Operating Expense
- 164.15
- Operating Income
- -21.7
- Net Income Before Taxes
- -19.38
- Net Income
- -14.76
- Diluted Normalized EPS
- -0.91
- Period
- 2025
- Total Assets
- 101.53
- Total Liabilities
- 17.82
- Total Equity
- 83.71
- Tangible Book Valueper Share Common Eq
- 12.74
- Period
- 2025
- Cashfrom Operating Activities
- -2.82
- Cashfrom Investing Activities
- 8.15
- Cashfrom Financing Activities
- -5.66
- Net Changein Cash
- -0.33
- Period
- 2024
- Total Revenue
- 104.34
- Selling/ General/ Admin Expenses Total
- 8.84
- Depreciation/ Amortization
- 10.67
- Other Operating Expenses Total
- 10.9
- Total Operating Expense
- 121.6
- Operating Income
- -17.26
- Net Income Before Taxes
- -19.11
- Net Income
- -21.73
- Diluted Normalized EPS
- -3.2
- Period
- 2024
- Total Assets
- 150.87
- Total Liabilities
- 54.19
- Total Equity
- 96.68
- Tangible Book Valueper Share Common Eq
- 14.12
- Period
- 2024
- Cashfrom Operating Activities
- 2.14
- Cashfrom Investing Activities
- -0.4
- Cashfrom Financing Activities
- -1.93
- Net Changein Cash
- -0.19
- Period
- 2023
- Total Revenue
- 129.57
- Selling/ General/ Admin Expenses Total
- 9.91
- Depreciation/ Amortization
- 13.42
- Other Operating Expenses Total
- 11.17
- Total Operating Expense
- 167.59
- Operating Income
- -38.02
- Net Income Before Taxes
- -42.27
- Net Income
- -38.62
- Diluted Normalized EPS
- -5.22
- Period
- 2023
- Total Assets
- 163.86
- Total Liabilities
- 45.57
- Total Equity
- 118.29
- Tangible Book Valueper Share Common Eq
- 17.46
- Period
- 2023
- Cashfrom Operating Activities
- -17.3
- Cashfrom Investing Activities
- 11.19
- Cashfrom Financing Activities
- -4.16
- Net Changein Cash
- -10.27
- Period
- 2022
- Total Revenue
- 137.13
- Selling/ General/ Admin Expenses Total
- 9.07
- Depreciation/ Amortization
- 14.51
- Other Operating Expenses Total
- 14.13
- Total Operating Expense
- 142.69
- Operating Income
- -5.56
- Net Income Before Taxes
- -6.14
- Net Income
- -5.33
- Diluted Normalized EPS
- -0.06
- Period
- 2022
- Total Assets
- 209.17
- Total Liabilities
- 51.29
- Total Equity
- 157.88
- Tangible Book Valueper Share Common Eq
- 28.17
- Period
- 2022
- Cashfrom Operating Activities
- 9.21
- Cashfrom Investing Activities
- -2.91
- Cashfrom Financing Activities
- -0.04
- Net Changein Cash
- 6.26
- Period
- 2021
- Total Revenue
- 202.38
- Selling/ General/ Admin Expenses Total
- 14.48
- Depreciation/ Amortization
- 15.82
- Other Operating Expenses Total
- 28.32
- Total Operating Expense
- 170.97
- Operating Income
- 31.41
- Net Income Before Taxes
- 29.49
- Net Income
- 22.78
- Diluted Normalized EPS
- 5.6
- Period
- 2021
- Total Assets
- 207.86
- Total Liabilities
- 48.94
- Total Equity
- 158.92
- Tangible Book Valueper Share Common Eq
- 37.73
- Period
- 2021
- Cashfrom Operating Activities
- 41.31
- Cashfrom Investing Activities
- -3.6
- Cashfrom Financing Activities
- -36.44
- Net Changein Cash
- 1.27
- Period
- 2020
- Total Revenue
- 167.27
- Selling/ General/ Admin Expenses Total
- 13.42
- Depreciation/ Amortization
- 17.34
- Other Operating Expenses Total
- 26.56
- Total Operating Expense
- 154.45
- Operating Income
- 12.82
- Net Income Before Taxes
- 4.74
- Net Income
- 3.63
- Diluted Normalized EPS
- 1.4
- Period
- 2020
- Total Assets
- 231.99
- Total Liabilities
- 90.52
- Total Equity
- 141.47
- Tangible Book Valueper Share Common Eq
- 33.25
- Period
- 2020
- Cashfrom Operating Activities
- 13.62
- Cashfrom Investing Activities
- -1.63
- Cashfrom Financing Activities
- -9.85
- Net Changein Cash
- 2.15
- Period
- 2019
- Total Revenue
- 169.57
- Selling/ General/ Admin Expenses Total
- 11.74
- Depreciation/ Amortization
- 19.31
- Other Operating Expenses Total
- 18.78
- Total Operating Expense
- 177.77
- Operating Income
- -8.2
- Net Income Before Taxes
- -16.1
- Net Income
- -12.03
- Diluted Normalized EPS
- -5.26
- Period
- 2019
- Total Assets
- 258.5
- Total Liabilities
- 153.2
- Total Equity
- 105.3
- Tangible Book Valueper Share Common Eq
- 43.31
- Period
- 2019
- Cashfrom Operating Activities
- 40.66
- Cashfrom Investing Activities
- -7.34
- Cashfrom Financing Activities
- -33.4
- Net Changein Cash
- -0.08
- Period
- 2025-03-31
- Total Revenue
- 39.14
- Selling/ General/ Admin Expenses Total
- 1.43
- Depreciation/ Amortization
- 3.9
- Other Operating Expenses Total
- 5.97
- Total Operating Expense
- 63.54
- Operating Income
- -24.4
- Net Income Before Taxes
- -22.12
- Net Income
- -14.29
- Diluted Normalized EPS
- 0.25
- Period
- 2025-03-31
- Total Assets
- 101.53
- Total Liabilities
- 17.82
- Total Equity
- 83.71
- Tangible Book Valueper Share Common Eq
- 12.74
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -2.82
- Cashfrom Investing Activities
- 8.15
- Cashfrom Financing Activities
- -5.66
- Net Changein Cash
- -0.33
- Period
- 2024-12-31
- Total Revenue
- 33.08
- Selling/ General/ Admin Expenses Total
- 1.47
- Depreciation/ Amortization
- 2.8
- Other Operating Expenses Total
- 6.3
- Total Operating Expense
- 26.84
- Operating Income
- 6.24
- Net Income Before Taxes
- 5.91
- Net Income
- 5.49
- Diluted Normalized EPS
- 0.03
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 39.39
- Selling/ General/ Admin Expenses Total
- 1.59
- Depreciation/ Amortization
- 2.81
- Other Operating Expenses Total
- 5.73
- Total Operating Expense
- 41.41
- Operating Income
- -2.02
- Net Income Before Taxes
- -1.31
- Net Income
- -3.23
- Diluted Normalized EPS
- -0.64
- Period
- 2024-09-30
- Total Assets
- 147.33
- Total Liabilities
- 56.61
- Total Equity
- 90.72
- Tangible Book Valueper Share Common Eq
- 13.42
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 0.35
- Cashfrom Investing Activities
- 1.89
- Cashfrom Financing Activities
- -2.11
- Net Changein Cash
- 0.13
- Period
- 2024-06-30
- Total Revenue
- 30.84
- Selling/ General/ Admin Expenses Total
- 1.62
- Depreciation/ Amortization
- 2.79
- Other Operating Expenses Total
- 5.35
- Total Operating Expense
- 31.83
- Operating Income
- -1
- Net Income Before Taxes
- -1.86
- Net Income
- -2.73
- Diluted Normalized EPS
- -0.55
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 22.82
- Selling/ General/ Admin Expenses Total
- 1.51
- Depreciation/ Amortization
- 2.66
- Other Operating Expenses Total
- 6.81
- Total Operating Expense
- 38.23
- Operating Income
- -15.42
- Net Income Before Taxes
- -15.97
- Net Income
- -15.3
- Diluted Normalized EPS
- -1.93
- Period
- 2024-03-31
- Total Assets
- 150.87
- Total Liabilities
- 54.19
- Total Equity
- 96.68
- Tangible Book Valueper Share Common Eq
- 14.12
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 2.14
- Cashfrom Investing Activities
- -0.4
- Cashfrom Financing Activities
- -1.93
- Net Changein Cash
- -0.19
- Period
- 2023-12-31
- Total Revenue
- 26.66
- Selling/ General/ Admin Expenses Total
- 1.55
- Depreciation/ Amortization
- 2.68
- Other Operating Expenses Total
- 4.13
- Total Operating Expense
- 28.29
- Operating Income
- -1.63
- Net Income Before Taxes
- -2.06
- Net Income
- -1.46
- Diluted Normalized EPS
- -0.29
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Lasa Supergenerics Technical
Moving Average
SMA
- 5 Day9.56
- 10 Day10.29
- 20 Day11.97
- 50 Day15.05
- 100 Day18.28
- 300 Day22.83
Lasa Supergenerics Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Vista Pharmaceuticals
- 10.34
- -0.35
- -3.27
- 16.59
- 9.1
- 63.35
- Jeevan Scientific Technology
- 39.39
- 0.9
- 2.34
- 67.8
- 36.5
- 62.36
- Lasa Supergenerics
- 10.29
- 0.49
- 5
- 33.49
- 8.52
- 51.55
- Deccan Health Care
- 20.3
- 0.83
- 4.26
- 39.1
- 16
- 47.48
- Crestchem
- 168.9
- 0.2
- 0.12
- 350
- 119.7
- 49.84
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Vista Pharmaceuticals
- -
- 0.28
- -9.58
- -76.17
- Jeevan Scientific Technology
- 984.75
- 1.25
- 9.04
- 8.68
- Lasa Supergenerics
- -
- 0.61
- -8.95
- -8.05
- Deccan Health Care
- 43.55
- 0.45
- 0.88
- 1.5
- Crestchem
- 18.47
- 6.74
- 43.55
- 8.53
Lasa Supergenerics Shareholding
Shareholding Pattern
*Promoter pledging: 11.08%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-May-25
- Audited Results
- 26-May-25
- Audited Results
- 13-Feb-25
- Quarterly Results
- 28-Jan-25
- Others
- 24-Jan-25
- To consider issue of Warrants
- 14-Nov-24
- Quarterly Results
- 14-Aug-24
- Quarterly Results
- 30-May-24
- Audited Results
- 13-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 22-Feb-25
- 30-Jan-25
- EGM
- 27-Sept-24
- 10-Sept-24
- AGM
- 27-Sept-23
- 05-Sept-23
- AGM
- 12-Jun-21
- 11-May-21
- COM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 11-Apr-22
- -
- 16-Sept-22
- 0.25
- 31-May-21
- -
- 15-Sept-21
- 0.25


